The FDA resolved the semaglutide shortage in late 2024 and the tirzepatide shortage in early 2025, which narrowed the compounding lane without eliminating legitimate, patient-specific compounding
For example, as this was written, we received news that the FDA had approved the GLP-1 Wegovy to treat the common liver condition called MASH (or, metabolic dysfunction-associated steatohepatitis)
In clinical trials, retatrutide users shed 22 to 29 percent of their body weight
J Clin Oncol 27(22):35843590 Dematteo RP et al (2009) Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial
Beyond weight loss, this treatment supports long-term metabolic health, energy, and confidence